QURE

Current Thesis

QURE is a binary-catalyst gene-therapy recovery trade, not a clean accelerating narrative. The stock cratered ~38% in a single session to ~$9.71 in March 2026 when the FDA demanded a full randomized, double-blind, sham-surgery-controlled Phase III for AMT-130 (Huntington's), killing the accelerated-approval path it had been priced on. Since then it has tripled to ~$30.18 (2026-06-04, mkt cap ~$1.90B), +47.5% over 30 days and +16.7% over 7 days (as of 2026-06-02), powered by (1) the 2026-05-12 ouster of FDA Commissioner Makary, which revived hope of a regulatory-regime reversal, (2) a UK MHRA approval pivot, and (3) the imminent 2026-06-18/19 AMT-260 epilepsy readout. We'd be buying hope-driven mean-reversion into a near-term binary — probe-only, not a fat pitch.

Bull Case

• The data is genuinely strong, the disease has zero approved disease-modifiers. June-2025 pivotal Phase I/II topline showed a statistically significant 75% slowing of disease progression on cUHDRS (p=0.003) vs a propensity-matched external control. If any accelerated path reopens, AMT-130 would be the first-ever Huntington's disease-modifying therapy — multi-billion TAM, orphan pricing.
• Regulatory-regime-change optionality. Makary — associated with aggressive drug rejections — resigned/was ousted 2026-05-12 (Diamantas acting commissioner); QURE jumped ~5% intraday. A Q2 2026 Type B FDA meeting was granted to discuss Phase III design AND a potential path off the 4-year data. A friendlier FDA could re-open accelerated approval.
• Second shot on goal: UK. 2026-04 MHRA pre-submission meeting completed; MAA filing planned Q3 2026 — a non-US approval route that doesn't depend on the hostile FDA stance.
• Near-term catalyst with prior signal. AMT-260 (refractory mesial temporal lobe epilepsy) first-cohort data 2026-06-18/19 at the Epilepsy Foundation Pipeline Conference. Prior single-patient case: 92% seizure reduction over 5 months, no serious safety events (May 2025). A clean cohort print is a fresh pipeline leg.
• Solvency is not the risk. Ended FY2025 with $622.5M cash, runway guided into H2 2029 — can fund a Phase III without an imminent raise.

Bear Case

• The primary thesis is officially broken. FDA stated (Dec 2025, reaffirmed Mar 2026) that Phase I/II vs external control is insufficient and "strongly recommended" a prospective randomized sham-controlled Phase III. That's years of delay and dilution risk on the flagship asset. Wells Fargo cut its rating on the feedback; securities-investigation headlines followed.
• Stretched into a binary. +47.5% in 30 days, ~3x off the ~$10 March low, into a 2026-06-18 readout — textbook peak-sentiment-into-event. AMT-260's prior signal is n=1; a cohort that regresses toward the mean disappoints a crowd positioned for another 90%+ number.
• The rally is hope, not confirmation. Makary's exit is a sentiment catalyst; the FDA has issued nothing reversing the Phase III demand. The Type B meeting could simply re-confirm "run the trial."
• ~$200M/yr burn against a multi-year Phase III erodes the cash cushion and raises eventual dilution odds.

Setup & Price Structure

• Price ~$30.18 (2026-06-04), day range $29.14–$31.00; 52-wk range $7.76/$8.73 – $71.50. Reclaimed the 200-day MA (~$25.16 on a March reading) on the recovery — structurally constructive but extended.
• Momentum hot/overbought: +16.7% (7d) and +47.5% (30d) as of 2026-06-02; RSI almost certainly elevated (>70). This is the "don't chase peak retail sentiment on a stretched name" zone of the trap matrix — the offset is that there is a dated catalyst (06-18).
• Base of the relief rally sits ~$19–22 (pre-Makary-news). A weekly close back below that band breaks the recovery structure.
• Pre-crash supply overhang from [entry redacted]–$71 holders is a long way up; this is a base-building recovery, not a new all-time-high breakout.

Catalyst Calendar (next 30 days)

• 2026-06-18/19 — AMT-260 epilepsy first-cohort data at Epilepsy Foundation Pipeline Conference. The near-term binary. (catalyst_date)
• Q2 2026 (by ~2026-06-30) — Type B FDA meeting on AMT-130 Phase III design / 4-year-data path. Minutes could land in-window; regime-change-reversal lottery ticket.
• Watch options flow into 06-18: rising call/put + IV ramp = smart money front-running the readout.

What Would Change Our Mind

• Upgrade to MEDIUM/HIGH: AMT-260 cohort print confirms the 90%+ seizure-reduction signal across multiple patients with clean safety, AND/OR Type B FDA minutes signal openness to a 4-year-data accelerated path. Either re-rates the name on substance, not hope.
• Downgrade/avoid: AMT-260 cohort disappoints (efficacy well below the n=1 92%, or a serious AE), or Type B minutes hard-confirm a full randomized sham-controlled Phase III with no accelerated route. Then the rally was a head-fake and supply overhead caps it.
• Hard invalidation: weekly close back below ~$22.

Correlation Notes

• FDA-regime-change basket: trades with Replimune (REPL) and ClearPoint Neuro (CLPT) on FDA-leadership headlines — all spiked on the 2026-05-08 WSJ "Trump planning to fire Makary" report and again on the 2026-05-12 resignation. CLPT is a direct read-through: its SmartFlow cannula is the delivery device for AMT-130's neurosurgical administration.
• Idiosyncratic, low beta to broad market/AI tape — moves on clinical/regulatory headlines, not macro. Effectively uncorrelated to the rest of a momentum book; sizing must reflect single-event gap risk (overnight readout = no stop protection).